Spravato, also known as esketamine, works differently from many traditional antidepressants. Instead of primarily targeting serotonin or norepinephrine pathways, esketamine acts on the brain’s glutamate system, specifically the N-methyl-D-aspartate (NMDA) receptor. Understanding this mechanism can help patients better understand why Spravato is used for certain forms of depression and why its effects can occur differently from conventional antidepressants.
NMDA receptors are specialized proteins found on nerve cells in the brain. They respond to glutamate, one of the brain’s major excitatory neurotransmitters. These receptors play important roles in communication between neurons, learning, memory, and synaptic plasticity.
Spravato contains esketamine, the S-enantiomer of ketamine. The FDA describes esketamine as a noncompetitive, nonselective NMDA receptor antagonist. However, the precise mechanism responsible for its antidepressant effects has not been fully established.
This distinction is important because researchers continue investigating exactly how changes in NMDA receptor activity translate into improvements in depressive symptoms.
After administration, esketamine reaches the brain and interacts with NMDA receptors. Researchers believe that blocking certain NMDA receptors can temporarily alter the balance between inhibitory and excitatory signaling in neural circuits.
One leading explanation involves NMDA receptors located on GABA-producing inhibitory interneurons. When esketamine reduces NMDA receptor activity on these cells, it may decrease inhibitory signaling and allow greater release of glutamate from other neurons. The additional glutamate can then stimulate AMPA receptors, another type of glutamate receptor.
This proposed process is one reason esketamine has attracted attention as a rapid-acting antidepressant treatment.
The effects of Spravato do not stop at the NMDA receptor. Increased glutamate signaling can activate AMPA receptors and initiate several downstream cellular processes associated with synaptic plasticity.
Research has linked these processes to signaling involving brain-derived neurotrophic factor, or BDNF, and pathways such as mammalian target of rapamycin complex 1, or mTORC1. These pathways are involved in the growth and strengthening of connections between neurons.
Researchers believe these changes in neural connectivity may contribute to antidepressant effects. However, the complete relationship between receptor activity, neuroplasticity, and clinical improvement remains an active area of research.
Many commonly prescribed antidepressants primarily influence monoamine neurotransmitters such as serotonin or norepinephrine. Spravato instead works through the glutamate system by interacting with NMDA receptors.
This different mechanism is particularly relevant for treatment-resistant depression. The FDA has approved Spravato for adults with treatment-resistant depression under specific treatment conditions. It is administered intranasally in a certified healthcare setting with monitoring because temporary sedation, dissociation, and other effects can occur.
The different mechanism does not mean Spravato is appropriate for everyone. A qualified provider must determine whether treatment is suitable based on the patient’s clinical circumstances.
Because Spravato affects brain signaling, some patients may experience temporary changes in perception, alertness, attention, or thinking after administration. Dissociation and sedation are recognized potential effects, which is why patients remain under observation following treatment.
Our Team can monitor patients during treatment and discuss questions about the medication’s effects, expected sensations, and overall treatment response. Care is individualized rather than based solely on the medication’s mechanism.
Dr. Michael Vines and the clinical team can evaluate treatment progress and consider how Spravato fits into a broader approach to managing treatment-resistant depression.
Spravato’s mechanism centers on esketamine’s interaction with NMDA receptors within the brain’s glutamate system. By altering NMDA receptor activity, esketamine may increase downstream glutamate and AMPA receptor signaling, potentially supporting processes involved in synaptic plasticity.
The exact antidepressant mechanism remains incompletely understood, so researchers continue studying how these molecular and cellular changes contribute to clinical improvement. Scottsdale TMS & Spravato provides supervised Spravato treatment with individualized monitoring and care, helping patients understand both the science behind treatment and what to expect during their sessions.
Dr. Vines has practiced psychiatry in Arizona for for over 25 years and has experience working with diverse populations that include children, adolescents, adults, geriatrics, SMI patients, and the chemically dependent.
September 12, 2026
